{
    "ticker": "CORT",
    "name": "Corcept Therapeutics Incorporated",
    "description": "Corcept Therapeutics Incorporated is a biopharmaceutical company headquartered in Menlo Park, California. Founded in 1998, Corcept focuses on developing innovative therapies for the treatment of severe metabolic and psychiatric disorders, particularly those associated with the overproduction of cortisol. The company's lead product, Korlym (mifepristone), is FDA-approved for the treatment of patients with Cushing's syndrome, a condition characterized by excessive cortisol levels. Korlym has demonstrated significant efficacy in controlling hyperglycemia and improving quality of life for patients suffering from this debilitating condition. Corcept is also engaged in developing new treatments that target the effects of cortisol on various diseases, including major depressive disorder and other psychiatric conditions. With a commitment to advancing patient care, Corcept emphasizes research and collaboration, aiming to bring new therapies to market that can improve the lives of patients suffering from cortisol-related disorders. The company's strategic focus on cortisol modulation positions it as a leader in addressing unmet medical needs in this field, and it continues to explore additional indications for its therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Menlo Park, California, USA",
    "founded": "1998",
    "website": "https://www.corcept.com",
    "ceo": "Robert J. McGarey",
    "social_media": {
        "twitter": "https://twitter.com/Corcept",
        "linkedin": "https://www.linkedin.com/company/corcept-therapeutics/"
    },
    "investor_relations": "https://investors.corcept.com",
    "key_executives": [
        {
            "name": "Robert J. McGarey",
            "position": "CEO"
        },
        {
            "name": "Richard A. L. B. R. H. M. O'Brien",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Korlym (mifepristone)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Corcept Therapeutics | Innovative Treatments for Cushing's Syndrome",
        "meta_description": "Explore Corcept Therapeutics, a leader in developing therapies for cortisol-related disorders. Learn about our innovative product Korlym and our commitment to patient care.",
        "keywords": [
            "Corcept",
            "Cushing's Syndrome",
            "Biopharmaceuticals",
            "Korlym",
            "Cortisol"
        ]
    },
    "faq": [
        {
            "question": "What is Corcept Therapeutics known for?",
            "answer": "Corcept Therapeutics is known for developing therapies for severe metabolic and psychiatric disorders, particularly those related to cortisol."
        },
        {
            "question": "What is Korlym?",
            "answer": "Korlym is the FDA-approved treatment for patients with Cushing's syndrome, helping to control hyperglycemia and improve quality of life."
        },
        {
            "question": "Where is Corcept headquartered?",
            "answer": "Corcept is headquartered in Menlo Park, California, USA."
        },
        {
            "question": "When was Corcept founded?",
            "answer": "Corcept was founded in 1998."
        }
    ],
    "competitors": [
        "VRTX",
        "AMGN",
        "REGN",
        "BIIB"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "ABBV",
        "JNJ"
    ]
}